- Home
- TNGX
as 07-26-2024 4:00pm EST
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 1.1B | IPO Year: | N/A |
| Target Price: | $14.86 | AVG Volume (30 days): | 896.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.91 - $13.03 | Next Earning Date: | 08-05-2024 |
| Revenue: | $37,232,000 | Revenue Growth: | 49.72% |
| Revenue Growth (this year): | -15.47% | Revenue Growth (next year): | 2.40% |
Stock Insider Trading Activity of Tango Therapeutics Inc. (TNGX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MVA Investors, LLC | TNGX | Jun 28 '24 | Sell | $8.68 | 95,000 | $824,600.00 | 108,793 | SEC Form 4 | |
| MVA Investors, LLC | TNGX | Jun 28 '24 | Sell | $8.87 | 110,731 | $982,183.97 | 203,793 | SEC Form 4 | |
| MVA Investors, LLC | TNGX | Jun 28 '24 | Sell | $8.57 | 29,000 | $248,530.00 | 314,524 | SEC Form 4 | |
| MVA Investors, LLC | TNGX | Jun 6 '24 | Sell | $7.24 | 63,000 | $456,120.00 | 420,524 | SEC Form 4 | |
| MVA Investors, LLC | TNGX | Jun 6 '24 | Sell | $6.88 | 77,000 | $529,760.00 | 343,524 | SEC Form 4 | |
| Calhoun Lesley Ann | TNGX | Director | Jun 5 '24 | Sell | $7.21 | 5,000 | $36,039.00 | 6,250 | SEC Form 4 |
| MVA Investors, LLC | TNGX | May 1 '24 | Sell | $7.43 | 75,000 | $557,250.00 | 618,524 | SEC Form 4 | |
| MVA Investors, LLC | TNGX | May 1 '24 | Sell | $7.56 | 75,000 | $567,000.00 | 543,524 | SEC Form 4 | |
| MVA Investors, LLC | TNGX | May 1 '24 | Sell | $7.61 | 60,000 | $456,600.00 | 483,524 | SEC Form 4 | |
| Third Rock Ventures IV, L.P. | TNGX | 10% Owner | Feb 20 '24 | Sell | $12.00 | 162,500 | $1,950,000.00 | 19,201,475 | SEC Form 4 |
| Weber Barbara | TNGX | Chief Executive Officer | Feb 6 '24 | Sell | $12.56 | 4,681 | $58,805.53 | 1,539,624 | SEC Form 4 |
| Weber Barbara | TNGX | Chief Executive Officer | Feb 6 '24 | Sell | $12.62 | 4,457 | $56,246.45 | 1,535,167 | SEC Form 4 |
| Beckman Daniella | TNGX | Chief Financial Officer | Feb 6 '24 | Sell | $12.56 | 1,908 | $23,969.44 | 134,214 | SEC Form 4 |
| Beckman Daniella | TNGX | Chief Financial Officer | Feb 6 '24 | Sell | $12.62 | 1,817 | $22,930.18 | 132,397 | SEC Form 4 |
| Barry Douglas | TNGX | General Counsel | Feb 6 '24 | Sell | $12.56 | 1,422 | $17,864.02 | 45,335 | SEC Form 4 |
| Barry Douglas | TNGX | General Counsel | Feb 6 '24 | Sell | $12.62 | 1,354 | $17,087.21 | 43,981 | SEC Form 4 |
| Crystal Adam | TNGX | See Remarks | Feb 6 '24 | Sell | $12.56 | 4,288 | $53,868.43 | 123,561 | SEC Form 4 |
| Crystal Adam | TNGX | See Remarks | Feb 6 '24 | Sell | $12.62 | 4,083 | $51,526.64 | 119,478 | SEC Form 4 |
Latest Tango Therapeutics Inc. News
TNGX Breaking Stock News: Dive into TNGX Ticker-Specific Updates for Smart Investing
Argus Research
2 days ago
Daily – Vickers Top Buyers & Sellers for 07/25/2024
Argus Research
4 days ago
Daily – Vickers Top Buyers & Sellers for 07/23/2024
Argus Research
7 days ago
Daily – Vickers Top Buyers & Sellers for 07/19/2024
Argus Research
7 days ago
Daily – Vickers Top Buyers & Sellers for 07/19/2024
Argus Research
24 days ago
Daily – Vickers Top Buyers & Sellers for 07/03/2024
CNW Group
2 months ago
Lotto 6/49 - $64 million up for grabs in the next draw!
Simply Wall St.
2 months ago
Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
AFP
2 months ago
Seoul says it will resume loudspeaker propaganda against North
Compare TNGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TNGX Tango Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.